Business
CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nPowered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data\n\n\nFirst tissue comprehensive genomic profiling test to offer genome-wide tumor methylation analysis\n\n\nAdvanced molecular profiling test requires 40% fewer tissue slides than industry norm, allowing researchers and oncologists to test more patients with less precious tissue\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nThroughout release, \"exome-wide\" should read as \"genome-wide\".\n\nThe updated release reads:\n\nGUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER\n\n\nPowered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data\n\n\nFirst tissue comprehensive genomic profiling test to offer genome-wide tumor methylation analysis\n\n\nAdvanced molecular profiling test requires 40% fewer tissue slides than industry norm, allowing researchers and oncologists to test more patients with less precious tissue\n\n\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Guardant360® Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis—including DNA, RNA, AI-powered PD-L1 and genome-wide methylation data—to provide researchers and cancer care teams with a more comprehensive view of cancer.\n\nPowered by the Guardant Infinity™ smart liquid biopsy platform, the advanced Guardant360 Tissue test enables insights beyond what can typically be found using tests that do not incorporate comprehensive analysis of epigenetics. These insights can apply to important classes of therapeutics, such as PARP-inhibitors and immunotherapies, as well as important new classes of therapies in late-stage development. The test also enables classification and subtyping of each individual tumor at a much higher resolution, potentially enabling a new era of precision oncology research and clinical applications.\n\nIn addition, since Guardant360 Tissue is built on the smart liquid biopsy platform, it requires 92% less tissue surface area for analysis than the industry norm. In a real-world assessment, more than 50% of tum...